JP2015510930A5 - - Google Patents

Download PDF

Info

Publication number
JP2015510930A5
JP2015510930A5 JP2015501758A JP2015501758A JP2015510930A5 JP 2015510930 A5 JP2015510930 A5 JP 2015510930A5 JP 2015501758 A JP2015501758 A JP 2015501758A JP 2015501758 A JP2015501758 A JP 2015501758A JP 2015510930 A5 JP2015510930 A5 JP 2015510930A5
Authority
JP
Japan
Prior art keywords
composition according
compound
pharmaceutical composition
substituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015501758A
Other languages
English (en)
Japanese (ja)
Other versions
JP6219918B2 (ja
JP2015510930A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/030933 external-priority patent/WO2013142202A1/en
Publication of JP2015510930A publication Critical patent/JP2015510930A/ja
Publication of JP2015510930A5 publication Critical patent/JP2015510930A5/ja
Application granted granted Critical
Publication of JP6219918B2 publication Critical patent/JP6219918B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015501758A 2012-03-19 2013-03-13 グリセロールエステルを含む医薬組成物 Expired - Fee Related JP6219918B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612731P 2012-03-19 2012-03-19
US61/612,731 2012-03-19
PCT/US2013/030933 WO2013142202A1 (en) 2012-03-19 2013-03-13 Pharmaceutical compositions comprising glycerol esters

Publications (3)

Publication Number Publication Date
JP2015510930A JP2015510930A (ja) 2015-04-13
JP2015510930A5 true JP2015510930A5 (enExample) 2017-04-06
JP6219918B2 JP6219918B2 (ja) 2017-10-25

Family

ID=49223212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501758A Expired - Fee Related JP6219918B2 (ja) 2012-03-19 2013-03-13 グリセロールエステルを含む医薬組成物

Country Status (8)

Country Link
US (1) US9993556B2 (enExample)
EP (1) EP2827867B1 (enExample)
JP (1) JP6219918B2 (enExample)
AU (1) AU2013235523B9 (enExample)
CA (1) CA2867123C (enExample)
ES (1) ES2764383T3 (enExample)
NZ (1) NZ630703A (enExample)
WO (1) WO2013142202A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2445502T (pt) * 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
ES2972387T3 (es) 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
AU2015231278B2 (en) * 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
SMT202100481T1 (it) 2014-08-18 2021-09-14 Alkermes Pharma Ireland Ltd Composizioni per profarmaci di aripiprazolo
WO2017119928A1 (en) * 2016-01-08 2017-07-13 Abon Pharmaceuticals, Llc Long acting injectable formulations
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN110669057A (zh) * 2018-07-02 2020-01-10 成都阿奇生物医药科技有限公司 一种奥氮平衍生物及其制备方法和用途

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2418499A (en) 1944-06-20 1947-04-08 Du Pont 2-alkoxymethylmercapto-thiazoles and thiazolines and a process for preparing the same
GB849541A (en) 1956-02-23 1960-09-28 Rohm & Haas Preparation of unsaturated cyclic urea derivatives
DE1273533B (de) 1962-09-08 1968-07-25 Hoechst Ag Verfahren zur Herstellung von N-(ª‡-Alkoxy-alkyl)-carbonsaeureamiden
NL128370C (enExample) 1964-08-28
US3523121A (en) 1967-03-09 1970-08-04 Rohm & Haas Certain 2-carbamoyl-3-isothiazolenes
US3573308A (en) 1969-04-03 1971-03-30 Hoffmann La Roche 3-lower alkoxy methyl-3,4-dihydro-4-hydroxy-4-aryl quinazolin-2(1h) ones and related compounds
US3957808A (en) 1969-09-03 1976-05-18 Rohm And Haas Company 3-alkoxyisothiazoles
US4727151A (en) 1974-06-24 1988-02-23 Interx Research Corporation Labile quaternary ammonium salts as prodrugs
US3998815A (en) 1974-06-24 1976-12-21 Interx Research Corporation 1-hydrocarbonoyloxymethyl-3-carbamoyl or 3-carboethoxy-pyridinium salts
US4204065A (en) 1975-09-22 1980-05-20 Interx Research Corporation Soft quaternary surface active agents and method of using same
US4260769A (en) 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS568318A (en) 1979-06-28 1981-01-28 Janssen Pharmaceutica Nv Non oral long acting composition of haloperidol and bromperidol derivative
DE3149010A1 (de) 1981-12-10 1983-07-07 A. Nattermann & Cie GmbH, 5000 Köln (+)-2-(1-(2,6-dichlorphenoxy)-ethyl)-1,3- diazacyclopent-2-en, dessen herstellung und seine verwendung in pharamazeutischen praeparaten
US4428935A (en) 1982-05-24 1984-01-31 Pfizer Inc. Penicillanic acid dioxide prodrug
IT1212743B (it) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Sali quaternari di derivati di benzo[ 1,4 ]diazepinonici,pirido [1,4]benzodiazepinonici,prido [1,5]benzodiazepinonici e loro atti vita' farmacologica
JPS602331A (ja) 1983-06-20 1985-01-08 Yoshino Kogyosho Co Ltd 飽和ポリエステル樹脂製壜の成形方法
US4760057A (en) 1983-06-23 1988-07-26 Merck & Co., Inc. (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs
DK302883D0 (da) 1983-06-30 1983-06-30 Hans Bundgaard Allopurinol prodrugs
DE3544134A1 (de) 1984-12-15 1986-06-19 Mitsubishi Chemical Industries Ltd., Tokio/Tokyo Verfahren zur herstellung von n-((alpha)-alkoxyethyl) pyrrolidon
GB8513754D0 (en) 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
DK588486A (da) 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4925860A (en) 1987-08-05 1990-05-15 E. I. Du Pont De Nemours And Company Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
US5350747A (en) 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
JP2800953B2 (ja) * 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5206386A (en) 1991-03-20 1993-04-27 Isp Investments Inc. Controlled release N-substituted pyrrolidone esters and process for the use thereof
MX9201991A (es) 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
TW226016B (enExample) 1991-12-30 1994-07-01 Sterling Winthrop Inc
US5462934A (en) 1992-03-09 1995-10-31 Takeda Chemical Industries Condensed heterocyclic ketone derivatives and their use
AU4534593A (en) 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
WO1994020508A1 (en) 1993-03-08 1994-09-15 Eisai Co., Ltd. Phosphonic acid derivatives
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
DE4439493A1 (de) 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
JP3571795B2 (ja) 1995-04-18 2004-09-29 株式会社日本触媒 N−(1−アルキルオキシアルキル)カルバメート類の気相分子内脱アルコール反応用触媒およびn−ビニルカルバメート類の製造方法
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
PL187926B1 (pl) 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
DE19619819A1 (de) 1996-05-16 1997-11-20 Boehringer Mannheim Gmbh Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltenden Arzneimittel
RU2186562C2 (ru) * 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
ES2210769T3 (es) 1997-06-13 2004-07-01 Cydex Inc. Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
AU752552C (en) 1997-09-30 2003-09-11 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
AU754965B2 (en) 1997-12-31 2002-11-28 University Of Kansas, The Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
PT1114028E (pt) 1998-08-26 2007-02-28 Aventis Pharma Ltd Aza-biciclos moduladores da inibição da adesão celular
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6656505B2 (en) 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
US20030049320A1 (en) 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
MXPA03005870A (es) 2001-02-14 2005-02-14 Warner Lambert Co Inhibirores de benzotiadiazina de metaloproteinasas de la matriz.
US20060293217A1 (en) 2001-03-19 2006-12-28 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
JP2005511477A (ja) 2001-03-19 2005-04-28 プラエシス ファーマシューティカルズ インコーポレーテッド 持続放出のための医薬調合物
EP1414798A2 (en) 2001-04-03 2004-05-06 Aryx Therapeutics Ultrashort-acting opioids for transdermal application
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ATE416168T1 (de) 2002-02-15 2008-12-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
NZ537995A (en) 2002-08-20 2007-11-30 Bristol Myers Squibb Co Inclusion complex of aripiprazole in a substituted b-cyclodextrin
EA200500342A1 (ru) 2002-09-17 2005-08-25 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Гетероциклические замещённые пиперазины для лечения шизофрении
US7148211B2 (en) 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
NZ540769A (en) 2002-12-18 2009-03-31 Algorx Pharmaceuticals Inc Administration of capsaicinoids for the treatment of pain
WO2004056305A2 (en) 2002-12-18 2004-07-08 Algorx Administration of capsaicinoids
DE10303669A1 (de) 2003-01-28 2004-07-29 Hans-Knöll-Institut für Naturstoff-Forschung e.V. Tetraalkylammoniumsalze vom Kohlensäureestertyp, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
ZA200508306B (en) 2003-05-23 2007-03-28 Otsuka Pharma Co Ltd Carbostyril derivatives and mood stabilizers for treating mood disorders
PL1651265T3 (pl) 2003-07-24 2008-10-31 Merial Ltd Formulacje szczepionek zawierających emulsję olej w wodzie
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CN100559182C (zh) * 2003-08-29 2009-11-11 株式会社东芝 显色试剂、浓度测定试剂盒、浓度测定方法和在该方法中使用的传感器芯片
BRPI0415531B8 (pt) 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
MXPA06007654A (es) 2003-12-31 2006-09-04 Warner Lambert Co Derivados de piperidina n-sustituidos.
CA2556160A1 (en) 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
US7169803B2 (en) 2004-03-15 2007-01-30 Bristol-Myers Squibb Company N-substituted prodrugs of fluorooxindoles
US7119214B2 (en) 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
GB2413795A (en) 2004-05-05 2005-11-09 Cipla Ltd Process for the preparation of rosiglitazone
WO2006037090A2 (en) 2004-09-28 2006-04-06 Purdue Research Foundation Drug-phosphate conjugates as prodrugs
EP2623095A1 (en) 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
WO2006090273A2 (en) 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
EP1891956B1 (en) 2005-06-13 2012-08-29 Dainippon Sumitomo Pharma Co., Ltd. Solubilization preparation
WO2007035348A2 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
EP1777222A1 (en) 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2007059111A2 (en) 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US20090068290A1 (en) 2006-08-31 2009-03-12 Michel Bourin Bifeprunox doses for treating schizophrenia
TW200829244A (en) 2006-09-15 2008-07-16 Astrazeneca Ab Therapeutic combinations 482
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
EP2121029A2 (en) 2006-12-05 2009-11-25 Neurogesx, Inc. Prodrugs and methods of making and using the same
EP2120909A2 (en) 2006-12-15 2009-11-25 Ordway Research Institute Treatments of therapy-resistant diseases comprising drug combinations
EP1961412A1 (en) 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Self-microemulsifying drug delivery systems
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
WO2008116024A2 (en) 2007-03-19 2008-09-25 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
HRP20130041T8 (en) 2007-04-04 2013-03-31 Merck Sharp & Dohme Corp. Therapeutic agents
US20100292316A1 (en) 2007-07-18 2010-11-18 Research Development Foundation Improved therapeutic methods and compositions comprising chroman ring compounds
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009052467A1 (en) 2007-10-19 2009-04-23 Board Of Regents Of The University Of Texas System Methods of identifying pi-3-kinase inhibitor resistance
WO2009060473A2 (en) * 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
CA2655335C (en) 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
AU2009288200A1 (en) 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
NZ594071A (en) 2009-01-26 2013-01-25 Egalet Ltd Controlled release formulations comprising morphine sulphate for continuous treatment of pain
US20100286136A1 (en) 2009-05-08 2010-11-11 Simon Jones Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders
JP5732453B2 (ja) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Nh酸性化合物のプロドラッグ
PT2445502T (pt) 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
AU2010313290A1 (en) 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
WO2011084851A1 (en) 2010-01-07 2011-07-14 Alkermes, Inc. Asenapine produrugs
US20110166128A1 (en) 2010-01-07 2011-07-07 Alkermes, Inc. Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders
EP2521545B1 (en) 2010-01-07 2019-11-27 Alkermes Pharma Ireland Limited Prodrugs of heteroaromatic compounds
WO2011084850A1 (en) 2010-01-07 2011-07-14 Alkermes, Inc. Prodrugs for the treatment of schizophrenia and bipolar disease
EP2521711B1 (en) 2010-01-07 2017-08-16 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
KR101792891B1 (ko) 2010-02-16 2017-11-20 하마마츠 포토닉스 가부시키가이샤 가스 농도 산출 장치 및 가스 농도 계측 모듈
JP5857040B2 (ja) 2010-05-04 2016-02-10 アルカーメス ファーマ アイルランド リミテッド 酸化ラクタム化合物の合成方法
NZ604423A (en) 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
ES2972387T3 (es) 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds

Similar Documents

Publication Publication Date Title
RU2017126606A (ru) Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбита
JP3274687B2 (ja) 9−ヒドロキシリスペリドン脂肪酸エステルの水性懸濁物
MX384954B (es) Composición auto-emulsionante de ácido graso ?3.
JP2019524670A5 (enExample)
PH12016500100B1 (en) Self-emulsifying composition of omega3 fatty acid
JP6333802B2 (ja) ベンジルアルコールを含む医薬組成物
TWI641395B (zh) 注射製劑
JP6654042B2 (ja) 貯蔵安定性が改善された医薬組成物
JP2017533968A5 (enExample)
JP2013513613A5 (enExample)
JP2009541223A5 (enExample)
JP2013531031A5 (enExample)
JP2015514808A5 (enExample)
JP2004530669A5 (enExample)
MX2012002534A (es) Derivados de (tio) morfolina como moduladores de esfingosin-1-fosfato.
JP2015510929A (ja) 脂肪酸エステルを含む医薬組成物
JP2015510930A (ja) グリセロールエステルを含む医薬組成物
RU2013130224A (ru) Фармацевтические композиции
ES2327528T3 (es) Composicion inyectable para el tratamiento del cancer.
EP2205215A2 (en) Docetaxel injectable composition, being absolutely free of ethanol
JP5593345B2 (ja) イソプロピルウノプロストンの分解抑制方法
JP2009523840A (ja) ピリド(3,2,1−ij)−ベンズオキサジアジン型の化合物を含む、抗感染剤溶液
RU2012155691A (ru) Производные сложного аминоэфира алкалоида и их лекарственные композиции
JP2014532063A5 (enExample)
JP2015522544A5 (enExample)